A Vision for Change: Exploring Biosimilars in Retinal Disease Management
Manage episode 381576895 series 3345006
Contenuto fornito da ReachMD. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da ReachMD o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Arghavan Almony, MD
The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.
…
continue reading
Guest: Arghavan Almony, MD
The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.
49 episodi